Search

Your search keyword '"Link, Brian A."' showing total 1,679 results

Search Constraints

Start Over You searched for: Author "Link, Brian A." Remove constraint Author: "Link, Brian A."
1,679 results on '"Link, Brian A."'

Search Results

2. Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation

3. Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL

5. Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment

6. Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium

7. Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study

8. Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironments

9. Surveillance imaging during first remission in follicular lymphoma does not impact overall survival

10. Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes

11. Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes

12. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

13. Genetic overlap between autoimmune diseases and non‐Hodgkin lymphoma subtypes

17. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma

18. Maintenance rituximab or observation after frontline treatment with bendamustine‐rituximab for follicular lymphoma

19. Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study

21. Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey

22. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma

23. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study

24. Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes

27. Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL

28. Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes

29. Molecular Classification of Relapsed DLBCL Reveals Novel Biologic Subgroups

30. DEK Regulates B-Cell Proliferative Capacity and Is Associated with Aggressive Disease in Low-Grade B-Cell Lymphoma

33. A genome-wide association study of marginal zone lymphoma shows association to the HLA region.

34. Repeatability and Reproducibility of In Vivo Cone Density Measurements in the Adult Zebrafish Retina

35. Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma

36. Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region

38. Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma

42. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition.

43. The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.

44. Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R

45. POSTER: ABCL-612 Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy

46. ABCL-612 Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy

47. POSTER: MCL-063 Multicohort Study of Conditional Survival and Cause of Death After Achieving Event-Free Survival at 24 Months (EFS24) in Patients With Mantle Cell Lymphoma (MCL)

48. MCL-063 Multicohort Study of Conditional Survival and Cause of Death After Achieving Event-Free Survival at 24 Months (EFS24) in Patients With Mantle Cell Lymphoma (MCL)

50. Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements

Catalog

Books, media, physical & digital resources